Zobrazeno 1 - 3
of 3
pro vyhledávání: '"11"'
Autor:
Qi Yang, Yan-Feng Ouyang, Si-Yuan Chen, Yong-Long Liu, Meng-Xia Zhang, Chong-yang Duan, Ming-Yuan Chen, Chenmei Gu, Rongzeng Liu, Yu-Long Xie, Mei Lin, Rou Jiang, Xiong Zou, Chao Lin, Pei Yu Huang, Xi Ding, Rui You, Yi-Jun Hua, Zhi-Qiang Wang, You-Ping Liu, Rui Sun
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundToripalimab is a humanized immunoglobulin G4 monoclonal antibody against programmed death 1. We aimed to investigate the efficacy and safety of toripalimab in combination with intensity-modulated radiotherapy (IMRT) for recurrent nasopharyn
Autor:
Yukio Kageyama, Minato Yokoyama, Soichiro Yoshida, Kazutaka Saito, Junichiro Ishioka, Yoh Matsuoka, Shohei Fukuda, Yasuhisa Fujii, Yosuke Yasuda, Toshiki Kijima
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
BackgroundThe dynamic change in C-reactive protein (CRP) levels, CRP kinetics, is a prognostic factor for metastatic renal cell carcinoma (mRCC) in the tyrosine kinase inhibitor era. We investigated the impact of early CRP kinetics on the efficacy of
Autor:
Limor Cohen, Cloud P. Paweletz, Biagio Ricciuti, Anika E. Adeni, David R. Walt, Julianna Supplee, Reiko Nishihara, Pasi A. Jänne, Padric M. Garden, Mariano Severgnini, Alissa Keegan, Mark M. Awad
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundBlood-based biomarkers of anti-solid tumor immune checkpoint blockade (ICB) response are lacking. We hypothesized that changes in systemic cytokine levels with the initial doses of programmed cell death protein 1 (PD-1) pathway inhibitors w